Summary
Latest filing:
Joseph Scheeren is Director of Barinthus Biotherapeutics plc. (BRNS). 1 SEC Form 4 filing on record, dated 9 September 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Joseph Scheeren has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Joseph Scheeren's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- BAKER BROS. ADVISORS LP - $317.75M of CELC open-market activity in the last 12 months
- Fairmount Funds Management LLC - $300.01M of ORKA open-market activity in the last 12 months
- A/S Genmab - $234.86M of MRUS open-market activity in the last 12 months
- Weiss Asset Management LP - $233.35M of AVDL open-market activity in the last 12 months
- August J. Troendle - $232.59M of MEDP open-market activity in the last 12 months
- James Edgemond - $201.52M of UTHR open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Joseph Scheeren?
Joseph Scheeren is a corporate insider, tracked as Director of Barinthus Biotherapeutics plc. (BRNS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Joseph Scheeren submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Joseph Scheeren's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Joseph Scheeren and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
